Press release
Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight
Download DelveInsight's comprehensive Clostridium Difficile Infections Pipeline Report @ [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Clostridium Difficile Infections Pipeline Report
* In March 2026- Vedanta Biosciences Inc . initiated a phase 3 RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
* In March 2026- Crestone Inc. announced a phase 2 study is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po) twice daily (bid) and vancomycin administered 125 mg PO 4 times daily (qid) in adults > or equal to 18 years of age with a primary episode or first recurrence of CDI. The study will investigate the plasma concentrations and HRQoL outcomes of CRS3123 and additional efficacy endpoints as secondary objectives.
* DelveInsight's Clostridium Difficile Infections pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Clostridium Difficile Infections treatment.
* The leading Clostridium Difficile Infections Companies such as Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
* Promising Clostridium Difficile Infections Pipeline Therapies such as VE303, Ibezapolstat, Vancomycin, SER-109, RBX2660, MK-6072, MK-3415A, Fidaxomicin and others.
Discover how the Clostridium Difficile Infections treatment paradigm is evolving @ [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Clostridium Difficile Infections Overview
Clostridium difficile (C. difficile) is a Gram-positive, spore-forming, anaerobic bacillus, which is widely distributed in the intestinal tract of humans and animals and in the environment. In the last decade, the frequency and severity of C. difficile infection has been increasing worldwide to become one of the most common hospital-acquired infections. Transmission of this pathogen occurs by the fecal-oral route and the most important risk factors include antibiotic therapy, old age, and hospital or nursing home stay. C. difficile colonizes in the large intestine of humans. Healthy adults with adequate immune response become asymptomatic carriers of the disease. Neonates also have a high rate of asymptomatic carrier rate, owing to a lack of intestinal receptors for C. difficile. The use of antibiotics alters the microbial flora of the large intestine, rendering it susceptible to infection by C. difficile, and the transmission of the disease occurs through the fecal-oral route.
Clostridium Difficile Infections Emerging Drugs Profile
* VE303: Vedanta Biosciences
VE303 is a potential first-in-class live biotherapeutic product candidate being developed by Vedanta Biosciences to prevent recurrence of Clostridioides difficile infection (CDI). It consists of a rationally-designed, defined bacterial consortium of 8 strains of clonal human commensal bacteria selected for their ability to provide colonization resistance to C. difficile. VE303 is administered orally in capsules and is produced under CGMP conditions from pure, clonal bacterial cell banks, yielding a standardized drug product. In a Phase II study, high-dose VE303 met its primary endpoint of preventing CDI recurrence at eight weeks in patients at high risk of recurrence. VE303 was generally well-tolerated in the study. Vedanta is currently enrolling patients into a pivotal Phase III registrational study called RESTORATiVE303 to evaluate the efficacy and safety of VE303 for the prevention of recurrent CD.
* Ibezapolstat: Acurx Pharmaceuticals
Ibezapolstat (formerly named ACX-362E) is our lead antibiotic candidate. Ibezapolstat is a first-in-class of a new class of Pol IIIC inhibitors which is in clinical development to treat C. difficile infections or CDI. In June 2018, ibezapolstat was designated by the US Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted Fast Track designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. Currently, the drug is in the Phase II stage of its development for the treatment of Clostridium Difficile Infections.
The Clostridium Difficile Infections Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Clostridium Difficile Infections with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Clostridium Difficile Infections Treatment.
* Clostridium Difficile Infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Clostridium Difficile Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Clostridium Difficile Infections market
Explore groundbreaking therapies and clinical trials in the Clostridium Difficile Infections Pipeline @ [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Clostridium Difficile Infections Companies
Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
Clostridium Difficile Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Clostridium Difficile Infections Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Clostridium Difficile Infections Pipeline Report
* Coverage- Global
* Clostridium Difficile Infections Companies- Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
* Clostridium Difficile Infections Pipeline Therapies such as VE303, Ibezapolstat, Vancomycin, SER-109, RBX2660, MK-6072, MK-3415A, Fidaxomicin and others.
* Clostridium Difficile Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Clostridium Difficile Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Clostridium Difficile Infections drug development? @ [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
1. Introduction
2. Executive Summary
3. Clostridium Difficile Infections: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Clostridium Difficile Infections- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. VE303: Vedanta Biosciences
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Ibezapolstat: Acurx Pharmaceuticals
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Clostridium Difficile Infections Key Companies
21. Clostridium Difficile Infections Key Products
22. Clostridium Difficile Infections- Unmet Needs
23. Clostridium Difficile Infections- Market Drivers and Barriers
24. Clostridium Difficile Infections- Future Perspectives and Conclusion
25. Clostridium Difficile Infections Analyst Views
26. Clostridium Difficile Infections Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=clostridium-difficile-infections-treatment-pipeline-shows-strong-momentum-as-20-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Clostridium Difficile Infections Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight here
News-ID: 4458884 • Views: …
More Releases from ABNewswire
High-Performance Steel Coil Series: Galvanized, PPGI, Carbon & Galvalume Coils B …
Inthe context of global industrial upgrading, infrastructure construction and green development, the need for high-quality and comprehensive Steel Coil [https://www.steelcreate.com/steel-coil/] is rising. From constructingbuildings to manufacturing home appliances, automotive, machinery manufacturing and hydraulic engineering,PPGI coil, Galvanized steel coil, prepainted galvanized steel coil, carbon steel coil and Galvalume Coil have become the fundamental building blocks of industry with their unique performance benefits, wide-ranging applications and cost-effectiveness. Jiedong Jurong Trading Co. Ltd.,…
M10 spring washers are essential for preventing bolts from loosening under high …
In long-term industrial equipment operation, vibration is one of the main causes of bolted joint failure. During continuous equipment operation, vibration energy is constantly transmitted to the connection points. Conventional fasteners often cannot withstand this constant dynamic load, and pretension gradually decreases, ultimately leading to bolt slippage and loosening, which can lead to equipment failure or accidents. M10 spring washers are professional bolt-loosening prevention components designed to address this issue.…
304 stainless steel lifting eyebolts: for hanging equipment in food processing p …
When installing overhead equipment in food processing facilities, safety and hygiene are two key requirements. Standard carbon steel eyebolts are highly susceptible to rust and corrosion in humid environments and in environments with frequent use of acidic and alkaline cleaning agents, which not only impacts equipment stability but also potentially contaminates the production environment. 304 stainless steel eyebolts, with their superior rust resistance and reliable load-bearing capacity, are the ideal…
Cytomegalovirus Infection Clinical Trial Pipeline Appears Robust With 15+ Key Ph …
DelveInsight's, "Cytomegalovirus (CMV) Infection Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in the Cytomegalovirus Infection pipeline landscape. It covers the Cytomegalovirus Infection pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cytomegalovirus Infection pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in understanding…
More Releases for Clostridium
EMEA Collagenase Clostridium Histolyticum Market - Outlook 2020-2033
The latest study released on the Global Collagenase Clostridium Histolyticum Market by HTF MI Research evaluates market size, trend, and forecast to 2033. The Collagenase Clostridium Histolyticum study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming challenges and about the competitors.
Consider…
Veterinary Clostridium Vaccine Market
The veterinary clostridium vaccine market plays a crucial role in the prevention of clostridial diseases in livestock and companion animals. Clostridial infections, caused by bacteria from the Clostridium genus, can lead to severe health issues and significant economic losses in the agriculture sector. Vaccination is one of the most effective methods to control these infections, which include conditions like enterotoxemia, tetanus, and gas gangrene. The growing awareness of animal health,…
Clostridium Diagnostics Market Analysis, Size, Share & Trends | 2031
In recent years, the global Clostridium Diagnostics Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Clostridium Diagnostics Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including Porters Five…
Clostridium Diagnostics Market to Witness Astonishing Growth by 2030
Clostridium Diagnostics market is projected to grow at a CAGR of 7.5% from 2024 to 2030. The growth in this market can be attributed to the increasing incidence of Clostridium-related diseases, rising demand for accurate and rapid diagnosis, and growing awareness about Clostridial infections. Important changes in the business allow key players to attain larger profits. This Clostridium Diagnostics Market study report is the best way to make changes with…
Clostridium Diagnostics Market - Empowering Precision, Defeating Infection: Adva …
Newark, New Castle, USA - new report, titled Clostridium Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Clostridium Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Clostridium Diagnostics market. The report offers an overview of the market, which…
Global Clostridium Difficile Immunoassays Market - Opportunities & Forecasts, 20 …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global clostridium difficile immunoassays market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was able…
